Attovia Therapeutics Inc., an early-stage biotech developing drugs aimed at immune system diseases, raises $289 million in a US initial public offering. Multiple outlets report that the company’s IPO is priced at the top of its marketed price range. Attovia is described as focused on conditions with significant unmet medical need, and it is backed by Goldman in the reporting. The reporting is consistent across sources on the size of the offering and the pricing outcome, with both outlets citing the same total proceeds and that the deal is set at the upper end of the company’s stated range. Beyond the immune-focused therapeutic focus and the stated rationale of unmet need, the available details in these sources are limited, and no additional information about the number of shares offered, use of proceeds, or lead underwriters is included in the provided excerpts. Overall, the articles agree on the core transaction terms: Attovia’s $289 million US IPO and the decision to price it at the top of its range.
Attovia Therapeutics raises $289 million in US IPO priced at top of range
Attovia Therapeutics Inc., an early-stage biotech developing drugs aimed at immune system diseases, raises $289 million in a US initial public offering. Multiple outlets report that the company’s IPO...
- Attovia Therapeutics Inc. raises $289 million in a US initial public offering.
- The IPO is priced at the top of the marketed price range.
- Attovia is an early-stage drug developer focused on immune system diseases.
- Both outlets describe the company as targeting areas with high unmet medical need.
- Goldman is reported as backing the biotech.
Attovia Therapeutics Inc., an early-stage drug developer focused on immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range.
2 hours agoAttovia Therapeutics Inc., an early-stage drug developer focused on immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range.
3 hours ago
Drought and heat drive Britain toward worst cereal harvest in four decades
Britain is heading for its worst cereal harvest in about four decades, driven by drought and unusually hot weather durin...
GM renews China joint venture with SAIC for 20 years
General Motors renews its long-running joint venture with China’s SAIC Motor for 20 years, following a restructuring of...
KOSPI swings on Middle East deal hopes and tech/AI stock movements
South Korea’s KOSPI opens and moves sharply during the latest session(s), driven by shifting expectations around a poten...